Skip to main content
Office of the Vice President for Research

University of Iowa Research Foundation

Site Main Navigation

  • About
    • Who We Are
    • Our Staff
    • Contact UIRF
  • For Innovators
    • When to Reach Out
    • Submit a Disclosure
    • From Research to Commercialization
    • Policies Regarding Intellectual Property
    • Innovator Education
  • For Industry
    • Featured Innovations
    • Available Technologies
  • Guidelines for Administrative Units
  • National Academy of Inventors
  • Technology Analyst Program

Breadcrumb

  1. Home

Therapeutics

Novel Molecules for the Prevention of Vascular Dysfunction

Permeation Enhancing Excipients for Oral Drug Delivery

First-in-Class Gene Therapy for Arrhythmogenic Right Ventricular Cardiomyopathy Caused by DSG2 Mutations

Novel Treatment for the Prevention and Treatment of Hospital Associated Deconditioning and Sarcopenia

Novel Process for Predicting Aptamer Specificity

Transdermal Patch for Sustained Naloxone Delivery

A Novel, Non-Opioid Strategy to Prevent Relapse in Opioid Use Disorder

Innovative Alpha-ketoglutarate-based Polymers for Intracellular Drug Delivery and Bone Tissue Regeneration

Lipid-Nanoparticle Therapy for Niemann-Pick Type C Disease

Improved Strategy for Prevention and Treatment of Metabolic Disorders

Butyrophilin Ligands with Improved Potency and Plasma Stability

Novel Payloads for Antibody Drug Conjugates

Pagination
  • Current page 1
  • Page 2
  • Next page ››
  • Last page Last »
RSS feed

University of Iowa Research Foundation

Office of the Vice President for Research

200 S. Capitol Street
Suite 2660
Iowa City, IA 52242

Phone: 319.335.4546

[email protected]

Social Media

  • LinkedIn

Admin Login

Footer tertiary

  • Thank a staff member
  • © 2026 The University of Iowa
  • Privacy Notice
  • UI Nondiscrimination Statement
  • Accessibility